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DOI 10.1016/j.cmet.2012.02.002In a recent report in Cell Metabolism,
Pihlajamaki et al. (2011) suggested an
important role of reduced SFRS10 gene
expression in human obesity. A low
cellular SFRS10 level was reported to
alter splicing of LPIN1 (encoding a key
regulator of lipid metabolism) in favor of
the lipogenic b isoform. Since such a
mechanism would provide an interesting
model for the causative link between
altered splicing and metabolic disease,
we tried to replicate the above findings
and measured SFRS10 expression in 47
human liver samples comprising the
whole spectrum of liver involvement in
obesity. In addition to 8 lean individuals
with normal liver histology (median BMI
25.5 kg/m2), we studied 8 obese individ-
uals with normal liver histology (‘‘healthy
obese,’’ median BMI 47.1 kg/m2), 7 obese
individuals with hepatic steatosis (median
BMI 41.5 kg/m2), 8 obese individuals with
nonalcoholic steatohepatitis (median BMI
47.8 kg/m2), and 16 paired samples taken
from 8 obese individuals before (median
BMI 41.5 kg/m2) and 4–9 months after
bariatric surgery (median BMI, 30.4 kg/
m2). Samples from individuals with
a BMI >30 kg/m2 at the time of sampling
were classified as obese (n = 34, median
BMI 46.1 kg/m2, mean 44.8 kg/m2, stan-
dard deviation 8.7 kg/m2). This group
included 16 samples from individuals in
the BMI range of 53 ± 7 kg/m2 (46–
60 kg/m2) at the time of sampling, which
was utilized by Pihlajamaki and
coworkers. Samples from individuals
with a BMI %30 kg/m2 by the time of
sampling were classified as ‘‘nonobese’’
(n = 13, median BMI 26.0 kg/m2, mean
25.6 kg/m2, standard deviation 3.0 kg/
m2). All samples were obtained following
a standardized protocol either directly inthe operating theater (open or laparo-
scopic biopsies) or at the bedside (percu-
taneous biopsies), ensuring an ex vivo
time of less than 60 s until shock freezing
in liquid nitrogen. All individuals provided
written, informedconsent prior to the biop-
sies, and institutional ethics approval was
obtained prior to the initiation of the study
(Ethikkommission der Medizinischen Fa-
kulta¨t Kiel, #D425/07, #A110/99). Liver
histology was assessed using standard
criteria for nonalcoholic fatty liver disease
(Kleiner et al., 2005), and insulin resistance
wasmeasured by way of the serum leptin-
to-adiponectin ratio (LAR, median 3.9,
range 0–19, interquartile range 0.6–6.4).
This parameter has been shown to be
strongly correlated with hyperinsulinemic
euglycemic clamp data (Finucane et al.,
2009). Expression of SFRS10 was evalu-
ated using semiquantitative RT-PCR and
real-time PCR (primers, CAGAACTACGG
CGAGCGGGAATC, ATGGCTGTGGCTGT
GCCGTC). The relative abundance of
LPIN1 splice variants was evaluated by
PCR and capillary electrophoresis with
laser-induced fluorescence detection
(CE-LIF) (Schindler et al., 2009), employing
primers that covered exons 4–7 (GCCG
TCAAGCAGCTCTGTA; GCATTTCTGGGT
TCTTCTGC).
Using PSPower (Dupont and Plummer,
1997) with standard deviation esti-
mates from our own data, the power to
detect the previously reported LPIN1
and SFRS10 expression differences
between obese and nonobese individuals
(0.8 units) in our samples turned out to
be virtually 100%. In spite of that, no
statistically significant differences in
terms of the parameters of interest were
observed between samples from obese
individuals (mean SFRS10 expressionCell Metabolism1.09, LPIN1 ratio [b/a] 0.30) and samples
from nonobese individuals (mean
SFRS10 expression 1.09, LPIN1 ratio
[b/a] 0.30, pSFRS10 = 0.97, pLPIN1 = 0.82,
see Figure S1 online). Similarly, no corre-
lation was detected between either liver
fat content or LAR on the one hand, and
SFRS10 expression or LPIN1 splicing on
the other (Figure S1, all p > 0.4). Finally,
we were able to assess the intraindividual
effects upon SFRS10 expression and
LPIN1 ratio associated with a massive
change of BMI in our paired samples
from eight individuals before and after
bariatric surgery (mean change in BMI
15.6 kg/m2, p = 5.6 3 106). Such a
comparison is particularly informative
because it would be inherently corrected
for any pertinent genetic variability.
Nevertheless, neither SFRS10 expression
(mean change 0.004, p = 0.90) nor LPIN1
ratio (mean change 0.03, p = 0.25) was
significantly affected by the drastic BMI
change seen in this subcohort.
In the original report, the specific candi-
date gene of subsequent analyses,
namely SFRS10, was ascertained via a
two-step approach. First, transcriptome-
wide expression analysis and GO-based
pathway analysis served to identify
‘‘RNA processing and splicing’’ as one of
the most downregulated pathways in 5
versus 8 liver samples (2 of them were
male) and 10 versus 7 muscle biopsies.
Notably, in a gene set enrichment analysis
(GSEA), a significant downregulation was
only seen for the liver, but not for the
muscle samples. In the second step,
those 13 genes with reduced expression
in both liver and muscle were selected
for further analysis. The final choice of
SFRS10 as the candidate for functional
studies was based upon mouse data in15, March 7, 2012 ª2012 Elsevier Inc. 265
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Letterswhich apparently only 2 of the 13 genes
showed a similar change of expression
as seen in humans. It was not reported
whether the other targets showed differ-
ential expression, or whether possible
changes went in the opposite direction
as compared to humans. No exact p value
was provided for SFRS10 in humans,
only ‘‘p < 0.05’’ was quoted. However,
given that 14,500 genes are typically
evaluated in transcriptome-wide expres-
sion analyses, control of either the
family-wise error rate or the false
discovery rate at the 5% level would
have required a much lower nominal
p value (e.g., p < 3.5 3 106 with Bonfer-
roni correction).
After selecting SFRS10 as their func-
tional candidate, the authors moved on
to demonstrate an altered expression of
lipogenic genes and increased plasma
triacylglyceride levels in a series of
elegant experiments in heterozygous
knockdown mice (Pihlajamaki et al.,
2011). Concentrating upon genes that
were known to regulate lipogenesis via
alternatively spliced isoforms, they identi-
fied Lpin1 as a likely target gene because
it harbors a conserved Sfrs10-binding266 Cell Metabolism 15, March 7, 2012 ª201motif in the alternatively spliced exon 6.
Evaluation of LPIN1 splicing in humans
was performed in lean (n = 6) and obese
(n = 14) individuals, although the relation-
ship between these and the other human
samples used in the screening stage
was not specified.
In conclusion, Pihlajamaki et al. (2011)
did not adhere to the current methodolog-
ical standards for the analysis and report-
ing of genome-wide transcriptome data
(Storey and Tibshirani, 2003), particularly
regarding the allowance for sampling
error and multiple statistical testing. In
addition to possible effects of sample
handling and sample quality, that formal
disregard appears to us to be a plausible
explanation for our failure to replicate the
original findings in our set of human liver
samples (which was the tissue showing
themore robust effect in humans, accord-
ing to the original report). This suggests
that, although animal experiments pro-
vide an excellent means of well-controlled
functional analysis, firm data in humans
are required before embarking upon
such extensive and time-consuming
experimental studies of human disease
or biology.2 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and
can be found with this article online at doi:10.
1016/j.cmet.2012.02.002.
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